Ocrevus 1 Vial 300 mg/10 ml

Ocrevus is a revolutionary treatment for people living with relapsing and primary progressive forms of multiple sclerosis (MS). It is a humanized monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to the disease process. In clinical trials, Ocrevus has been proven to reduce the frequency of relapses, slow disability progression, and improve the overall quality of life for people with MS. Ocrevus is administered by a healthcare professional every six months via an intravenous infusion. It is the only MS therapy approved by the U.S Food and Drug Administration (FDA) that can be administered in one hour or less, and is the first and only approved therapy for both relapsing and primary progressive forms of MS.

Ocrevus helps reduce the frequency of relapses, slow disability progression, and improve the overall quality of life for people with MS.